CN105497030A - Trimetazidine new use in prevention and treatment of sepsis-caused cardiac insufficiency - Google Patents
Trimetazidine new use in prevention and treatment of sepsis-caused cardiac insufficiency Download PDFInfo
- Publication number
- CN105497030A CN105497030A CN201510638569.5A CN201510638569A CN105497030A CN 105497030 A CN105497030 A CN 105497030A CN 201510638569 A CN201510638569 A CN 201510638569A CN 105497030 A CN105497030 A CN 105497030A
- Authority
- CN
- China
- Prior art keywords
- trimetazidine
- sepsis
- cardiac
- cardiac insufficiency
- myocardial
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The present invention discloses new use of trimetazidine having cardiac protection effect in prevention and treatment of sepsis-caused cardiac insufficiency. Trimetazidine can inhibit the inflammatory reaction and reduce generation of myocardial cell reactive oxygen by inhibiting infiltration and proliferation of myocardial macrophages, and reduces myocardial cell damage and myocardial cell apoptosis. Prophylactic administration and therapeutic study results show that the trimetazidine not only significantly reduces myocardial cell edema, reduces the myocardial cell apoptosis, improves myocardial contractile function, has the curative effect of improving ejection fraction, and also has significant curative effects to improve blood pressure and reduce death rates.
Description
Technical field
The present invention relates to new medicine use field, be specially the novelty teabag of trimetazidine in control sepsis cardiac insufficiency.
Background technology
Trimetazidine Hydrochloride (Trimetazidine), chemical name is: 1-(2,3,4-trimethoxybenzyl group) piperazine dihydrochloride.The energy (ATP) of normal myocardium supplies 60% ~ 70% from free fatty beta-oxidation, and 20% ~ 25% is glucose oxidase, and 5% ~ 10% is glycolysis.The oxygen consumption that free-fat acid oxidase produces equivalent ATP is higher than the oxygen consumption of glucose oxidase, and high-level free-fat acid oxidase obviously can suppress the speed of glucose oxidase.Sympathetic activation during myocardial ischemia, catecholamine levels raises, and then causes blood free fatty acid level to raise; Cardiac muscle energy resource supply Free Fat acid oxidase is increased to 80% ~ 90%; Glycolytic and glucose oxidase be coupled imbalance, cause H in myocardial cell
+, Ca
2+and Na
+overload, causes cell acidosis and infringement, myocardium work efficiency is reduced, increase of simultaneously consuming energy.Therefore, optimize energy metabolism of myocardial, especially suppress free-fat acid oxidase, strengthen myocardial glucose metabolism and be conducive to alleviating the tissue injury that myocardial ischemia causes, improve myocardial function.Trimetazidine can suppress fatty acids metabolism, fatty acids metabolism is reduced, thus make cardiac muscle with glucose metabolism for main produce power, when at coronary artery pathological changes, myocardial oxygen delivery is restricted, improve the availability of oxygen, produce more energy-rich phosphate bond, with alleviate myocardial ischemia symptom, and maintain the survival of cardiac muscle and the function of heart.In addition, the S-acetyl-coenzyme-A that trimetazidine makes fatty acids metabolism produce reduces, thus stimulates pyruvic dehydrogenase, indirectly makes glucose oxidase be strengthened.
Trimetazidine can also provide the effect of metabolic myocardial cell protection, mainly by reducing H in cell
+, Ca
2+, Na
+overload, improve the utilization rate of lactic acid, the ketoboidies reducing cell produces, and effectively suppresses the cell acidosis caused by anoxia to realize.In expeirmental myocardial ischemia model, trimetazidine can improve myocardial contraction, reduces infarct size; The reduction of pH value and ATP in T suppression cell; Reduce neutrophil accumulation, suppress the infringement of radical pair myocardial cell, increase myocardial cell to the tolerance of hypoxia stress.Trimetazidine also has and maintains mitochondrial normal function, to make in myocardial cell oxygen-derived free radicals produce to reduce, to suppress in cardiac muscular tissue the effects such as neutrophil infiltration, all favourable to its function of resisting myocardial ischemia.
Trimetazidine can reduce vascular resistance, increases coronary flow and surrounding loop blood flow, promotes the generation of myocardial metabolism and cardiac energy; Heart working load can be lowered, reduce the consumption of myocardial oxygen consumption and cardiac energy, thus improve the equilibrium of supply and demand of myocardium oxygen.Still can increase the toleration to cardiotonic glycoside.Clinically be applicable to arteria coronaria functional defect, angina pectoris, old myocardial infarction etc.Can use with Folium Digitalis Purpureae with severe cardiac functional defect person.
Sepsis refers to that various pathogenic microorganism or its toxin are present in blood or tissue, that body is to a kind of systemic inflammatory response infected, further developing and can cause septic shock and multiple organ dysfunction syndrome, is one of clinical Cavity in Critical Patients main causes of death.Have 40% ~ 50% to merge cardiac dysfunction in sepsis patient, person accounts for 7% wherein to occur severe heart failure.Up to now, its mechanism is not yet come to a conclusion.Bacteriotoxin, cytokine etc. cause heart muscle perfusion deficiency, energy metabolism of myocardial obstacle and apoptosis of cardiac muscle etc. by different approach, are the important mechanisms that sepsis causes heart and injury.Energy metabolism of myocardial obstacle is the initiating link of sepsis cardiac insufficiency myocardial cell injury, is to cause and promote that cardiac dysfunction occurs, the key factor of development.There is no the medicine for the treatment of sepsis cardiac insufficiency at present.
Summary of the invention
In order to overcome above-mentioned deficiency of the prior art, the invention discloses trimetazidine, in control sepsis cardiac insufficiency, there is the novelty teabag protecting medicine as cardiac function, in the sepsis cardiac insufficiency that antibacterial is brought out, having significant protective effect.
The object of the present invention is achieved like this:
The novelty teabag that have as cardiac function protection medicine of trimetazidine in control sepsis cardiac insufficiency:
Energy metabolism of myocardial obstacle is the initiating link of sepsis cardiac insufficiency myocardial cell injury, is to cause and promote that cardiac dysfunction occurs, the key factor of development.Think that following factor is participated at present:
1. mitochondrial function damage: myocardial mitochondria is the main place of energy metabolism of myocardial, and during sepsis, myocardial mitochondria also there occurs a series of change, mitochondria dysfunction is (as oxidative phosphorylation damage, Ca
2+overload) be the key mechanism that energy metabolism of myocardial changes.That reduces in the severe sepsis course of disease is cell oxygen consumption but not tissue oxygen confession.Generate adenosine triphosphate (adenosinetriphosphate, ATP) because > 90% oxygen consumes in mitochondrion, therefore, mitochondria dysfunction may play an important role in sepsis myocardiac inhibition.
2. myocardium disorders of lipid metabolism: normal myocardium ATP derives from mitochondrial oxidative metabolism, wherein fatty acid is 60% ~ 80%, and pyruvate oxidation is 10% ~ 40%, and glycolysis is little.During sepsis, myocardial cell energy oxidative metabolism preferentially utilizes glucose energy supply by preferentially utilizing free fatty (freefattyacid, FA) to become.The reason that FA is oxidized minimizing is that per-compound enzyme body increment activated receptor activity reduces and causes participation FA to transport the down regulation of gene expression with metabolism.
3. myocardium abnormal carbohydrate metabolism: during sepsis, the substrate of energy metabolism of myocardial changes, becomes the substrate preferentially utilizing glucose as energy metabolism from preferentially utilizing FA.Although FA is not so good as glucose effectively as energy source, need the oxygen of many consumption 10% could produce the ATP of equivalent, FA oxidation minimizing can not be completely compensatory by glucose metabolism enhancing institute.During sepsis, myocardial cell zymetology changes, and myocardium abnormal carbohydrate metabolism and cardiac muscle can be caused to there is progressive energy decline, finally cause the reduction of cardiac function.
Trimetazidine of the present invention can also by suppressing myocardial macrophages to infiltrate, breeding, and inflammation-inhibiting reacts, and reduces the generation of myocardial cell activity oxygen simultaneously, alleviates the myocardial cell injury that response to oxidative stress causes, and reduces apoptosis of cardiac muscle.
Compared with prior art, preventive administration and therapeutic studies result all show, trimetazidine not only has the curative effect significantly alleviating myocardial cell edema, reduce apoptosis of cardiac muscle, improve myocardium shrinkage function, improve ejection fraction, also has the significant curative effect improving hypotension, reduce mortality rate.And the curative effect of its intravenous formulations is compared, oral formulations effect is similar.
Accompanying drawing explanation
The oral trimetazidine of Fig. 1 is to the preventive effect of sepsis cardiac insufficiency.Figure 1A is that myocardium HE dyes and cell area measures.Preventative oral trimetazidine can improve sepsis cardiac insufficiency mouse cardiac myocytes edema.Figure 1B is myocardium TUNEL staining examine apoptosis.Preventative oral trimetazidine can improve sepsis cardiac insufficiency mouse cardiac myocytes apoptosis.Fig. 1 C is echocardiography cardiac function.Preventative oral trimetazidine can improve sepsis cardiac insufficiency mouse heart ejection fraction and shortening fraction declines.Fig. 1 D is echocardiography heart internal diameter.Preventative oral trimetazidine can improve sepsis cardiac insufficiency mouse cardiac muscle edema.Fig. 1 E is that cardiac catheter detects cardiac function.Preventative oral trimetazidine can improve sepsis cardiac insufficiency mouse heart function damage.
The oral trimetazidine of Fig. 2 is to the therapeutical effect of sepsis cardiac insufficiency.Fig. 2 A is echocardiography cardiac function.Oral trimetazidine treatment can improve sepsis cardiac insufficiency mouse heart ejection fraction and shortening fraction declines.Fig. 2 B is echocardiography heart internal diameter.Oral trimetazidine treatment can improve sepsis cardiac insufficiency mouse cardiac muscle edema.Fig. 2 C is that cardiac catheter detects cardiac function.Oral trimetazidine treatment can improve sepsis cardiac insufficiency mouse heart function damage.Fig. 2 D is arteria caudalis monitoring of blood pressure.Oral trimetazidine treatment can improve sepsis cardiac insufficiency mice hypotension state.Fig. 2 E rate for survival.Oral trimetazidine treatment can improve the survival rate of sepsis cardiac insufficiency mice.
Fig. 3 intravenous injection trimetazidine is to the Prevention and Curation effect of sepsis cardiac insufficiency.Fig. 3 A is that cardiac catheter detects cardiac function.Preventative intravenous injection trimetazidine can improve sepsis cardiac insufficiency mouse heart function damage.Fig. 3 B is that cardiac catheter detects cardiac function.The treatment of intravenous injection trimetazidine can improve sepsis cardiac insufficiency mouse heart function damage.Fig. 3 C is arteria caudalis monitoring of blood pressure.The treatment of intravenous injection trimetazidine can improve sepsis cardiac insufficiency mice hypotension state.Fig. 3 D rate for survival.The treatment of intravenous injection trimetazidine can improve the survival rate of sepsis cardiac insufficiency mice.
The oral trimetazidine of Fig. 4 is to the inhibitory action of sepsis cardiac insufficiency inflammatory reaction.Fig. 4 A is that peripheral blood inflammatory factor detects.Trimetazidine can improve the systemic inflammatory response of sepsis cardiac insufficiency mice.Fig. 4 B is that heart tissue inflammatory factor detects.Trimetazidine can improve the cardiac inflammatory reaction of sepsis cardiac insufficiency mice.Fig. 4 C is the macrophages infiltration that SABC detects cardiac muscle.Trimetazidine can reduce the macrophages infiltration of sepsis cardiac insufficiency mouse cardiac muscle.
The oral trimetazidine of Fig. 5 is to the inhibitory action of oxidative macrophage stress and inflammatory reaction.Fig. 5 A is that DHE staining examine oxidative macrophage stress.Trimetazidine can improve the response to oxidative stress of macrophage.Fig. 5 B is that macrophage inflammatory factor detects.Trimetazidine can improve the inflammatory reaction of macrophage.
Detailed description of the invention
Further describe the present invention below in conjunction with specific embodiment, advantage and disadvantage of the present invention will be more clear along with description.But these embodiments are only exemplary, do not form any restriction to scope of the present invention.It will be understood by those skilled in the art that and can modify to the details of technical solution of the present invention and form or replace down without departing from the spirit and scope of the present invention, but these amendments and replacement all fall within the scope of protection of the present invention.
The oral trimetazidine of embodiment 1 is to the preventive effect of sepsis cardiac insufficiency
C57 mice is divided into 4 groups at random: 1) matched group (normal saline gavage), 2) trimetazidine matched group (TMZ, 20mg/kg, oral administration gavage, three times on the one), 3) and lipopolysaccharide group (LPS, 15mg/kg, lumbar injection), 4) and trimetazidine prevention group (TMZ+LPS, TMZ20mg/kg, oral administration gavage, three times on the one, gives LPS15mg/kg after 3 days, lumbar injection), often organize 8.
C57 mice, after SPF environment raises one week, starts to give prevention oral administration gavage trimetazidine, gives LPS after 3 days.LPS lumbar injection, after 6 hours, adopts toy high frequency cardiac ultrasonic and Millar cardiac catheter system to carry out cardiac function detection.Put to death animal subsequently, after heart fixed by formalin, embedding, section, adopt H & E dyeing to carry out cardiomorphology detection; And adopt TUNEL test kit to detect apoptosis.
Result shows, and H & E dyeing shows the sepsis cardiac insufficiency mouse cardiac myocytes Mild edema that trimetazidine can improve LPS and causes, and cell area increases (Figure 1A).Meanwhile, TUNEL detects and shows that trimetazidine can suppress sepsis cardiac insufficiency mouse cardiac myocytes apoptosis (Figure 1B).And cardiac ultrasonic result shows that the ejection fraction of sepsis cardiac insufficiency mice and shortening fraction decline, and trimetazidine can play a role in improving (Fig. 1 C), trimetazidine can also improve sepsis cardiac insufficiency mouse cardiac muscle edema (Fig. 1 D).The result that Millar cardiac catheter detects is consistent therewith, and trimetazidine improves sepsis cardiac insufficiency mouse heart function damage (Fig. 1 E).
Experiment conclusion: confirm that trimetazidine peroral dosage form involved in the present invention has the effect of prevention sepsis cardiac insufficiency.
The oral trimetazidine of embodiment 2 is to the therapeutical effect of sepsis cardiac insufficiency
C57 mice is divided into 4 groups at random: 1) matched group (normal saline gavage), 2) trimetazidine matched group (TMZ, 20mg/kg, oral administration gavage, three times on the one), 3) and lipopolysaccharide group (LPS, 15mg/kg, lumbar injection), 4) and trimetazidine treatment group (LPS+TMZ, LPS15mg/kg, after lumbar injection 6 hours, starts to give TMZ20mg/kg, oral administration gavage, three times on the one, continue 24 hours), often organize 8.
C57 mice, after SPF environment raises one week, gives LPS lumbar injection, starts to give trimetazidine 20mg/kg after 6 hours, oral administration gavage, three times on the one, continue 24 hours, period adopted toy tail vein pressure measuring instrument to compress into row monitoring to Mouse Blood every 6 hours.And adopt toy high frequency cardiac ultrasonic and Millar cardiac catheter system to carry out cardiac function detection when terminal.
Result shows, cardiac ultrasonic result shows that the ejection fraction of sepsis cardiac insufficiency mice and shortening fraction decline, and trimetazidine can play therapeutical effect (Fig. 2 A), trimetazidine can also improve sepsis cardiac insufficiency mouse cardiac muscle edema (Fig. 2 B).The result that Millar cardiac catheter detects is consistent therewith, and trimetazidine improves sepsis cardiac insufficiency mouse heart function damage (Fig. 2 C).
Another batch of C57 mice is divided into 4 groups at random: 1) matched group (normal saline gavage), 2) trimetazidine group (TMZ, 20mg/kg, oral administration gavage, three times on the one), 3) and lipopolysaccharide group (LPS, 15mg/kg, lumbar injection), 4) and trimetazidine treatment group (LPS+TMZ, LPS15mg/kg, after lumbar injection 6 hours, starts to give TMZ20mg/kg, oral administration gavage, three times on the one, continue 3 days), often organize 20.
C57 mice, after SPF environment raises one week, gives LPS lumbar injection, starts to give trimetazidine 20mg/kg, oral administration gavage after 6 hours, three times on the one, continues 3 days, observes its death condition subsequently, calculates survival curve.
Result shows, the survival rate of the sepsis cardiac insufficiency mice that LPS causes declined the fastest in 24 hours, and thereafter continuous decrease to being less than 10%, and the survival rate of trimetazidine treatment group sepsis cardiac insufficiency mice in 24 hours a little more than non-treatment group, and thereafter maintain be stable at more than 50%.
Experiment conclusion: confirm that trimetazidine peroral dosage form involved in the present invention has the effect for the treatment of sepsis cardiac insufficiency, and the survival rate of sepsis cardiac insufficiency can be significantly improved.
Embodiment 3 intravenous injection trimetazidine is to the Prevention and Curation effect of sepsis cardiac insufficiency
In preventive effect, C57 mice is divided into 4 groups at random: 1) matched group (normal saline tail vein injection), 2) trimetazidine matched group (TMZ, 20mg/kg, tail vein injection, 2 times on the one), 3) lipopolysaccharide group (LPS, 15mg/kg, lumbar injection), 4) trimetazidine prevention group (TMZ+LPS, TMZ20mg/kg, tail vein injection, 2 times on the one, LPS15mg/kg is given, lumbar injection after 3 days), often organize 8.
C57 mice, after SPF environment raises one week, starts to give prevention tail vein injection trimetazidine, gives LPS after 3 days.LPS lumbar injection, after 6 hours, adopts toy high frequency cardiac ultrasonic and Millar cardiac catheter system to carry out cardiac function detection.
In therapeutical effect, C57 mice is divided into 4 groups at random: 1) matched group (normal saline tail vein injection), 2) trimetazidine matched group (TMZ, 20mg/kg, tail vein injection, 2 times on the one), 3) and lipopolysaccharide group (LPS, 15mg/kg, lumbar injection), 4) trimetazidine treatment group (LPS+TMZ, LPS15mg/kg, after lumbar injection 6 hours, start to give TMZ20mg/kg, tail vein injection, 2 times on the one, continue 24 hours), often organize 8.
C57 mice, after SPF environment raises one week, gives LPS lumbar injection, starts to give trimetazidine 20mg/kg after 6 hours, tail vein injection, 2 times on the one, continue 24 hours, period adopted toy tail vein pressure measuring instrument to compress into row monitoring to Mouse Blood every 6 hours.And adopt Millar cardiac catheter system to carry out cardiac function detection when terminal.
Result shows, and Millar cardiac catheter testing result shows, tail vein injection trimetazidine improves sepsis cardiac insufficiency mouse heart function damage (Fig. 3 A and 3B).
Another batch of C57 mice is divided into 4 groups at random: 1) matched group (normal saline tail vein injection), 2) trimetazidine group (TMZ, 20mg/kg, tail vein injection, 2 times on the one), 3) and lipopolysaccharide group (LPS, 15mg/kg, lumbar injection), 4) and trimetazidine treatment group (LPS+TMZ, LPS15mg/kg, after lumbar injection 6 hours, starts to give TMZ20mg/kg, tail vein injection, 2 times on the one, continue 3 days), often organize 20.
C57 mice, after SPF environment raises one week, gives LPS lumbar injection, starts to give trimetazidine 20mg/kg, tail vein injection after 6 hours, 2 times on the one, continues 3 days, observes its death condition subsequently, calculates survival curve.
Result shows, the survival rate of the sepsis cardiac insufficiency mice that LPS causes declined the fastest in 24 hours, and thereafter continuous decrease to being less than 10%, and the survival rate of trimetazidine treatment group sepsis cardiac insufficiency mice in 24 hours a little more than non-treatment group, and thereafter maintain be stable at about 50%.
Experiment conclusion: confirm that trimetazidine intravenous form involved in the present invention has the effect for the treatment of sepsis cardiac insufficiency, the survival rate of sepsis cardiac insufficiency can be significantly improved, and effect is similar compared with peroral dosage form.
The oral trimetazidine of embodiment 4 is to the inhibitory action of sepsis cardiac insufficiency inflammatory reaction
C57 mice is divided into 4 groups at random: 1) matched group (normal saline gavage), 2) trimetazidine matched group (TMZ, 20mg/kg, oral administration gavage, three times on the one), 3) and lipopolysaccharide group (LPS, 15mg/kg, lumbar injection), 4) and trimetazidine intervention group (TMZ+LPS, TMZ20mg/kg, oral administration gavage, three times on the one, gives LPS15mg/kg after 3 days, lumbar injection), often organize 8.
C57 mice, after SPF environment raises one week, starts to give oral administration gavage trimetazidine, gives LPS after 3 days.LPS lumbar injection put to death animal after 6 hours, retained peripheral blood, adopted ELISA kit to detect the content of peripheral blood inflammatory factor (TNF α, MCP-1, IL-1 β and IL-6).Extract heart tissue RNA, adopt real-timePCR to detect the expression of the myocardial inflammation factor (TNF α, MCP-1, IL-1 β and IL-6).And heart tissue embedding, section are fixed to formalin, adopt F4/80 dyeing to carry out the detection of heart macrophages infiltration.
Result shows, and ELISA result shows the sepsis cardiac insufficiency mouse systemic inflammatory reaction (Fig. 4 A) that trimetazidine can improve LPS and causes.Further, real-timePCR detects the sepsis cardiac insufficiency mouse heart inflammatory reaction (Fig. 4 B) showing that trimetazidine can improve LPS and causes.F4/80 coloration result shows that trimetazidine can reduce the macrophages infiltration (Fig. 4 C) of sepsis cardiac insufficiency mouse cardiac muscle further.
Experiment conclusion: confirm that trimetazidine involved in the present invention can suppress the inflammatory reaction of whole body and heart local.
The oral trimetazidine of embodiment 5 is to the inhibitory action of oxidative macrophage stress and inflammatory reaction
Extract C57 mouse primary peritoneal macrophage; be divided into 6 groups at random: 1) matched group; 2) trimetazidine matched group (TMZ; 20 μMs), 3) NAC matched group (NAC, 5 μMs); 4) lipopolysaccharide group (LPS; 5 μ g/ml), 5) trimetazidine intervention group (LPS+TMZ), 6) NAC intervention group (LPS+NAC).
Primary peritoneal macrophage, according to above grouping, gives after TMZ or NAC intervene 1 hour, to give LPS and intervene, adopt DHE dye, detection of active oxygen content after 6 hours, assess response to oxidative stress respectively.And extract cell RNA, adopt real-timePCR to detect the expression of the myocardial inflammation factor (TNF α, MCP-1, IL-1 β and IL-6).
Result shows, and DHE coloration result shows that trimetazidine can improve the response to oxidative stress of the macrophage of LPS induction, and curative effect and oxygen free radical scavenger (NAC) similar (Fig. 5 A).Further, real-timePCR detects and shows that trimetazidine can improve the inflammatory reaction of the macrophage of LPS induction, and curative effect and oxygen free radical scavenger (NAC) similar (Fig. 5 B).
Experiment conclusion: confirm that trimetazidine involved in the present invention can suppress oxidative macrophage stress and inflammatory reaction, improve macrophage function.
Claims (4)
1. trimetazidine, is characterized in that: the novelty teabag in control sepsis cardiac insufficiency with cardiac function protecting.
2. the trimetazidine according to claim 1 novelty teabag for the treatment of as sepsis cardiac insufficiency, it is characterized in that: trimetazidine can by suppressing myocardial macrophages to infiltrate, breeding, inflammation-inhibiting reacts, reduce the generation of myocardial cell activity oxygen simultaneously, alleviate myocardial cell injury, reduce apoptosis of cardiac muscle.Preventive administration and therapeutic studies result all show, trimetazidine not only has the curative effect significantly alleviating myocardial cell edema, reduce apoptosis of cardiac muscle, improve myocardium shrinkage function, improve ejection fraction, also has the significant curative effect improving hypotension, reduce mortality rate.
3. the medicine of control sepsis cardiac insufficiency according to claim 1, it is characterized in that, it is ejection preparation.
4. the application of the active component thing described in claim 1 or 3 in the medicine of preparation control sepsis cardiac insufficiency.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510638569.5A CN105497030A (en) | 2015-09-28 | 2015-09-28 | Trimetazidine new use in prevention and treatment of sepsis-caused cardiac insufficiency |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510638569.5A CN105497030A (en) | 2015-09-28 | 2015-09-28 | Trimetazidine new use in prevention and treatment of sepsis-caused cardiac insufficiency |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105497030A true CN105497030A (en) | 2016-04-20 |
Family
ID=55705591
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510638569.5A Pending CN105497030A (en) | 2015-09-28 | 2015-09-28 | Trimetazidine new use in prevention and treatment of sepsis-caused cardiac insufficiency |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105497030A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103919852A (en) * | 2014-04-04 | 2014-07-16 | 田芳 | Blending method of heart-protecting pill mixed powder containing musk for preventing and treating chronic cardiac insufficiency and heart failure |
| CN104138379A (en) * | 2013-05-06 | 2014-11-12 | 常州高新技术产业开发区三维工业技术研究所有限公司 | An anti-hypoxic pharmaceutical composition and applications thereof |
-
2015
- 2015-09-28 CN CN201510638569.5A patent/CN105497030A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104138379A (en) * | 2013-05-06 | 2014-11-12 | 常州高新技术产业开发区三维工业技术研究所有限公司 | An anti-hypoxic pharmaceutical composition and applications thereof |
| CN103919852A (en) * | 2014-04-04 | 2014-07-16 | 田芳 | Blending method of heart-protecting pill mixed powder containing musk for preventing and treating chronic cardiac insufficiency and heart failure |
Non-Patent Citations (1)
| Title |
|---|
| CHEN CHEN 等: "Trimetazidine attenuates cardiac dysfunction in endotoxemic mice through a modulation of inflammatory response", 《岭南心血管病杂志》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Fisher et al. | Ascorbic acid attenuates lipopolysaccharide-induced acute lung injury | |
| Ascheim et al. | Thyroid hormone metabolism in patients with congestive heart failure: the low triiodothyronine state | |
| Sung et al. | Therapeutic potential of resveratrol in heart failure | |
| Cohn et al. | Variability of hemodynamic responses to acute digitalization in chronic cardiac failure due to cardiomyopathy and coronary artery disease | |
| Booke et al. | Nitric oxide synthase inhibition versus norepinephrine for the treatment of hyperdynamic sepsis in sheep | |
| Zhu et al. | Glucose-insulin-potassium preserves systolic and diastolic function in ischemia and reperfusion in pigs | |
| Majid et al. | Insulin and glucose in the treatment of heart-failure | |
| Codolosa et al. | Update on ranolazine in the management of angina | |
| Kalra et al. | Efficacy of metabolic modulators in ischemic heart disease: an overview | |
| Schofield et al. | Role of metabolically active drugs in the management of ischemic heart disease | |
| Marik | Patterns of death in patients with sepsis and the use of hydrocortisone, ascorbic acid, and thiamine to prevent these deaths | |
| Khan et al. | Rescue of heart lipoprotein lipase-knockout mice confirms a role for triglyceride in optimal heart metabolism and function | |
| Chavez et al. | Effect of hyperglycemia and fatty acid oxidation inhibition during aerobic conditions and demand-induced ischemia | |
| CN105497030A (en) | Trimetazidine new use in prevention and treatment of sepsis-caused cardiac insufficiency | |
| Knight et al. | From antianginal drugs to myocardial cytoprotecthre agents | |
| Simonsen | Haemodynamic effects of ICI 118,587 in cardiomyopathy. | |
| Wu et al. | SGLT2 Inhibitors: New Hope for the Treatment of Acute Myocardial Infarction? | |
| Ramanathan et al. | Glucose-insulin-potassium solution improves left ventricular mechanics in diabetes | |
| US3329567A (en) | Synergistic effect of adenylic nucleotides in digitalis therapy | |
| Tabrizchi | The influence of tumour necrosis factor-α on the cardiovascular system of anaesthetized rats | |
| CN103550222A (en) | Applications of chaetocin in preparing medicament for preventing and treating diabetes | |
| Ostrominski et al. | Clinical and mechanistic potential of sodium-glucose co-transporter 2 (SGLT2) inhibitors in heart failure with preserved ejection fraction | |
| d'Agostino et al. | Altered cardiac metabolic phenotype after prolonged inhibition of NO synthesis in chronically instrumented dogs | |
| Silva et al. | Effects of L-arginine-enriched total enteral nutrition on body weight gain, tumor growth, and in vivo concentrations of blood and tissue metabolites in rats inoculated with Walker tumor in the kidney | |
| Law et al. | Adrenergic, insulin, and work interactions with adenosine's effects on in situ myocardial glucose uptake |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20160420 |